Abstracts tagged "Psoriatic arthritis"

Abstract Number: 1428 • ACR Convergence 2023
Guselkumab Provides Clinically Meaningful Improvents in Patient-Reported Outcomes in Patients with Active Psoriatic Arthritis Who Are Inadequate Responders to Tumour Necrosis Factor Inhibitors: Results Through One Year of a Phase 3b, Randomized, Controlled Study (COSMOS)
Laure Gossec¹, Xenofon Baraliakos², James Galloway³, Lars Erik⁴, Vilija Oke⁵, Petros Sfikakis⁶, Emmanouil Rampakakis⁷, Mohamed Sharaf⁸, Frederic Lavie⁹ and Iain McInnes¹⁰, ¹Sorbonne Université and Pitié Salpêtrière Hospital, Paris, France, ²Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ³King's College London, London, United Kingdom, ⁴Bispebjerg-Frederiksberg Hospital, Vedbæk, Denmark, ⁵Karolinska Institutet, Stockholm, Sweden, ⁶National Kapodistrian University of Athens Medical School, Athens, Greece, ⁷JSS Medical Research, Saint-Laurent, QC, Canada, ⁸Immunology, Janssen MEA, Dubai, United Arab Emirates, ⁹The Janssen Pharmaceutical Companies of Johnson & Johnson, Paris, France, ¹⁰University of Glasgow, Glasgow, United Kingdom
Background/Purpose: In the Phase 3b COSMOS trial, guselkumab (GUS), a fully human IL-23p19 inhibitor (i), was associated with significantly greater improvements vs placebo (PBO) in…
Abstract Number: 1642 • ACR Convergence 2023
Identifying Distinct Phenotypes in Psoriatic Arthritis: A Study from the Psoriatic Arthritis Research Consortium (PARC) Cohort
Paras Karmacharya¹, Daniel W. Byrne², Alisa Stephens-Shields³, Leslie Crofford⁴, M. Elaine Husni⁵, Jose Scher⁶, Ethan Craig³, Robert Fitzsimmons³, Soumya Reddy⁷, Marina Nighat Magrey⁸, Jessica A Walsh⁹ and Alexis R Ogdie³, ¹Vanderbilt University, Nashville, TN, ²Vanderbilt University Medical Center, Nashville, TN, ³University of Pennsylvania, Philadelphia, PA, ⁴Vanderbilt University Medical Center, Melbourne, AR, ⁵Cleveland Clinic / Department of Rheumatic and Immunologic Diseases, Cleveland, OH, ⁶New York University School of Medicine, New York, NY, ⁷NYU School of Medicine, New York, NY, ⁸Case Western Reserve University, University Hospitals, Cleveland, OH, ⁹Salt Lake City Veterans Affairs Health and University of Utah Health, Division of Rheumatology, Salt Lake City, UT
Background/Purpose: Despite an increasing number of therapeutic options, less than one-third of patients with PsA achieve remission. A major cause of non-response is that PsA…
Abstract Number: 1792 • ACR Convergence 2023
Identifying Synovial Fluid Micro-RNA Signature That Distinguishes Psoriatic Arthritis from Osteoarthritis
Darshini Ganatra¹, Anas Samman¹, David Nasri¹, Sara Rahmati¹, Omar Cruz Correa¹, Rohan Machhar¹, Rajiv Gandhi², Mohit Kapoor³ and Vinod Chandran⁴, ¹Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, ON, Canada, ²Schroeder Arthritis Institute, Krembil Research Institute, University Health Network and Division of Orthopaedics, Department of Surgery, University of Toronto, Toronto, ON, Canada, ³Schroeder Arthritis Institute, University Health Network and Department of Surgery, University of Toronto, Toronto, ON, Canada, ⁴Schroeder Arthritis Institute, Krembil Research Institute, University Health Network and Division of Rheumatology, Department of Medicine, University of Toronto, Toronto, ON, Canada
Background/Purpose: Psoriatic Arthritis (PsA) is an inflammatory arthritis and shares several clinical features with Osteoarthritis (OA), the most common form of arthritis. This often leads…
Abstract Number: 2234 • ACR Convergence 2023
Disagreement Between Patient and Physician Global Assessment over Time in Psoriatic Arthritis: Insight into Treatment Priorities
Proton Rahman¹, Laura Coates², Peter Nash³, Atul Deodhar⁴, Francois Nantel⁵, Emmanouil Rampakakis⁶, Louis Bessette⁷, A. Marilise Marrache⁸, Frederic Lavie⁹, May Shawi¹⁰ and William R Tillett¹¹, ¹Craig Dobbin Research Institute, Memorial University, St. John's, NL, Canada, ²University of Oxford, Oxford, United Kingdom, ³School of Medicine, Griffith University, Brisbane, Australia, ⁴Division of Arthritis and Rheumatic Disease, Oregon Health & Science University, Portland, OR, ⁵Nantel Medsci Consult, Consultant, Montreal, QC, Canada, ⁶McGill University, Department of Pediatrics / JSS Medical Research, Scientific Affairs, Montreal, QC, Canada, ⁷Centre de l'Ostéoporose et de Rhumatologie de Québec, Quebec City, QC, Canada, ⁸Janssen Inc., Rheumatology and Biologics, Dollard-des-Ormeaux, QC, Canada, ⁹The Janssen Pharmaceutical Companies of Johnson & Johnson, Paris, France, ¹⁰Immunology, Janssen Research & Development, LLC, Titusville, NJ, ¹¹Department of Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom
Background/Purpose: The PsA core domain set developed by the Outcome Measures in Rheumatology working group includes musculoskeletal disease, fatigue, physical function, and structural damage, of…
Abstract Number: 2250 • ACR Convergence 2023
Bimekizumab Impact on Health-Related Quality of Life and Physical Function in Patients with Active Psoriatic Arthritis Who Were Biologic DMARD‑Naïve or Had Inadequate Response or Intolerance to TNF-α Inhibitors: 1-Year Results from Two Phase 3, Randomized Studies
Dafna Gladman¹, Laure Gossec², M. Elaine Husni³, Lars Erik⁴, Paolo Gisondi⁵, Alice B. Gottlieb⁶, Diamant Thaçi⁷, Barbara Ink⁸, Rajan Bajracharya⁸, Jérémy Lambert⁹, Nikos Lyris⁸, Jason Coarse¹⁰ and William R Tillett¹¹, ¹Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Department of Medicine, University of Toronto, Toronto, ON, Canada, ²Sorbonne Université and Pitié Salpêtrière Hospital, Paris, France, ³Cleveland Clinic / Department of Rheumatic and Immunologic Diseases, Cleveland, OH, ⁴Bispebjerg-Frederiksberg Hospital, Vedbæk, Denmark, ⁵Università di Verona, Verona, Italy, ⁶Icahn School of Medicine at Mount Sinai, New York, NY, ⁷Institute and Comprehensive Center for Inflammation Medicine, University of Lübeck, Lübeck, Germany, ⁸UCB Pharma, Slough, United Kingdom, ⁹UCB Pharma, Irigny, France, ¹⁰UCB Pharma, Morrisville, NC, ¹¹Department of Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom
Background/Purpose: PsA has a substantial negative impact on patient (pt) health-related quality of life (HRQoL);1 symptom control, preventing structural damage, and normalizing physical and social…
Abstract Number: 0174 • ACR Convergence 2023
Evaluation of Healthcare Utilization in Members with Rheumatoid Arthritis, Psoriatic Arthritis, and Systemic Lupus Erythematosus
Jean Park, W. Cliff Rutter, Elisea Avalos-Reyes, Chen Liu, Will Cavers, Dorothea Verbrugge and Kjel Johnson, CVS Health, Woonsocket, RI
Background/Purpose: Healthcare utilization is increasing among patients with rheumatic diseases. While several studies have assessed healthcare utilization in rheumatoid arthritis (RA) patients, few studies have…
Abstract Number: 0490 • ACR Convergence 2023
Racial/Ethnic Differences in Psoriatic Arthritis Patient Responses Regarding Disease Burden, Treatment, and Communication with Care Team
Iris Navarro-Millán¹, Gail Kerr², Jeffrey Carter³, Laura Simone⁴ and Marykate Nelson⁵, ¹Weill Cornell Medicine, Hospital for Special Surgery, New York, NY, ²Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, ³PRIME Education, Boynton Beach, FL, ⁴PRIME, Omaha, NE, ⁵PRIME Education, Drexel Hill, PA
Background/Purpose: The purpose of this study was to examine differences in perceptions of psoriatic arthritis (PsA) disease burden as well as various aspects of care…
Abstract Number: 0506 • ACR Convergence 2023
Patient and Physician Global Assessment of Psoriatic Arthritis Disease Activity: High Concordance in an ArLAR Multinational Study
Nelly Ziade¹, Noura Abbas², Lina El Kibbi³, Avin Maroof⁴, Bassel Elzorkany⁵, Nizar Ani⁶, ASAL ADNAN⁷, NABAA IHSAN JAWAD AWADH⁷, Faiq Gorial⁸, Nada Alchama⁹, Chafika Haouichat¹⁰, Fatima Alnaimat¹¹, Suad Hannawi¹², Saed Atawnah¹³, HUSSEIN HALABI¹⁴, Manal Al-Mashaleh¹⁵, Laila Aljazwi¹⁶, Ahmed Abogamal¹⁷, laila Ayoub¹⁸, Elyes Bouajina¹⁹, Rachid Bahiri²⁰, Sahar Saad²¹, Maha Sabkar²¹, Krystel Aouad²², Laure Gossec²³ and Ihsane Hmamouchi²⁴, ¹Saint-Joseph University, Beirut, Lebanon, ²Saint Joseph University Beirut, Beirut, Lebanon, ³Specialized Medical Center, Riyadh, Saudi Arabia, ⁴Kurdistan University Hawler, Erbil, Iraq, ⁵Private (BZRC), Cairo, Egypt, ⁶Baghdad College of Medicine, Baghdad, Iraq, ⁷Baghdad Teaching Hospital, Baghdad, Iraq, ⁸University of Baghdad, Baghdad, Iraq, ⁹Ebn Al Nafiss Hospital, Damascus, Syria, ¹⁰Faculty of Medicine El Mahdi Si Ahmed, Blida, Algeria, ¹¹University of Jordan, Amman, Jordan, ¹²Kuwait Hospital, Department of Rheumatology, Dubai, United Arab Emirates, ¹³Al ahli hospital, Hebron, Palestine, Hebron, Palestinian Territories, ¹⁴King Faisal Specialist Hospital & Research Centre, Jeddah, Saudi Arabia, ¹⁵Royal Medical Services, Amman, Jordan, ¹⁶Tripoli, Tripoli, Libya, ¹⁷Saudi German Hospital Dubai, Dubai, United Arab Emirates, ¹⁸University of Tripoli, Tripoli, Libya, ¹⁹Farhat Hached Hospital of Sousse, Sousse, Tunisia, ²⁰Department of Rheumatology, El Ayachi Hospital Medical University, Sale, Morocco, ²¹King Hamad University Hospital, Bahrain, Bahrain, ²²Saint George Hospital University Medical Center, Beirut, Lebanon, ²³Sorbonne Université and Pitié Salpêtrière Hospital, Paris, France, ²⁴Rheumatology Unit, Lalla Aicha Temara Hospital, Temara, Morocco
Background/Purpose: In patients with psoriatic arthritis (PsA), discordance between physicians and patients when assessing disease activity has been described as frequent, mainly in European and…
Abstract Number: 0965 • ACR Convergence 2023
Comparing Predictors of DAPSA28, DAPSA66/68 and DAS28-CRP Remission at 6 Months in Bio-naive Patients with Psoriatic Arthritis Initiating a TNFi in Clinical Practice – Results from the EuroSpA Collaboration
Stylianos Georgiadis¹, Louise Linde², Lykke Ørnbjerg¹, Simon Horskjær Rasmussen¹, Johan Askling³, Brigitte Michelsen⁴, Daniela Di Giuseppe³, Johan Karlsson Wallman⁵, Bente Glintborg⁶, Anne Gitte Loft⁷, Miguel Bernardes⁸, Carolina Ochôa Matos⁹, Dan Nordstrom¹⁰, Laura Kuusalo¹¹, Burkhard Moeller¹², Michael Nissen¹³, Bjorn Gudbjornsson¹⁴, Thorvardur Love¹⁵, Florenzo Iannone¹⁶, Tore Kvien¹⁷, Ziga Rotar¹⁸, Isabel Castrejon¹⁹, Gary Macfarlane²⁰, Marleen van de Sande²¹, Merete Hetland¹ and Mikkel Østergaard²², ¹Copenhagen Center for Arthritis Research, Rigshospitalet, Copenhagen, Denmark, ²Rigshospitalet Glostrup, Glostrup, Denmark, ³Karolinska Institutet, Stockholm, Sweden, ⁴Rigshospitalet Glostrup; Diakonhjemmet Hospital; Sørlandet Hospital, Copenhagen, Denmark, ⁵Lund University and Skåne University Hospital, Lund, Sweden, ⁶Rigshospitalet Glostrup, University of Copenhagen, Virum, Denmark, ⁷Aarhus University, Horsens, Denmark, ⁸Rheumatology Department, Centro Hospitalar e Universitário de São João, Porto, Portugal, ⁹Centro Académico de Medicina de Lisboa, Lisbon, Portugal, ¹⁰Helsinki University Hospital, Helsinki, Finland, ¹¹Centre for Rheumatology and Clinical Immunology, University of Turku and Turku University Hospital, Turku, Finland, ¹²Inselspital - University Hospital Bern, Bern, Switzerland, ¹³Geneva University Hospitals, Geneva, Switzerland, ¹⁴Centre for Rheumatology Research, University Hospital, Reykjavik, Iceland, ¹⁵Landspitali University Hospital and the University of Iceland, Reykjavik, Iceland, ¹⁶Rheumatology Unit, Department of Precision and Regenerative Medicine and Ionian Area, University of Bari "Aldo Moro", Bari, Italy, ¹⁷Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, ¹⁸University Medical Centre Ljubljana, Ljubljana, Slovenia, ¹⁹Universitario Gregorio Marañón, Madrid, Spain, ²⁰Aberdeen Centre for Arthritis and Musculoskeletal Health (Epidemiology Group), University of Aberdeen, Aberdeen, United Kingdom, ²¹Amsterdam UMC, University of Amsterdam, Department of Rheumatology & Clinical Immunology and Department of Experimental Immunology, Amsterdam Infection & Immunity Institute; Amsterdam Rheumatology & Immunology Center (ARC), Academic Medical Center, Amsterdam, Netherlands, ²²Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet; University of Copenhagen, Copenhagen, Denmark
Background/Purpose: The Disease Activity index for PSoriatic Arthritis based on 66/68 joints (DAPSA66/68) and the Disease Activity Score in 28 joints with C-reactive protein (DAS28-CRP)…
Abstract Number: 1412 • ACR Convergence 2023
Improvements in Patient-Reported Outcomes Through 6 Months of Guselkumab Treatment in Patients with Active Psoriatic Arthritis: Real-World Data from the CorEvitas Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry
Philip J. Mease¹, Alexis R Ogdie², John Tesser³, Natalie shiff⁴, Iris Lin⁵, Soumya Chakravarty⁶, Mike Kelleman⁷, Rhiannon Dodge⁷, Robert McLean⁷, Aaron Broadwell⁸, Arthur Kavanaugh⁹ and Joseph F. Merola¹⁰, ¹Swedish Medical Center/Providence St. Joseph Health and University of Washington School of Medicine, Seattle, WA, ²University of Pennsylvania, Philadelphia, PA, ³Arizona Arthritis & Rheumatology Associates, Phoenix, AZ, ⁴Immunology, Janssen Scientific Affairs, LLC / Adjunct, Community Health and Epidemiology, University of Saskatchewan, Horsham, PA, ⁵Janssen, Horsham, PA, ⁶Immunology, Janssen Scientific Affairs, LLC / Division of Rheumatology, Drexel University College of Medicine, Villanova, PA, ⁷CorEvitas, LLC, Waltham, MA, ⁸Department of Rheumatology, Rheumatology and Osteoporosis Specialists, Shreveport, LA, ⁹Division of Rheumatology, Allergy, and Immunology, University of California San Diego, La Jolla, CA, ¹⁰Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Guselkumab (GUS) has demonstrated significant efficacy across disease domains in controlled clinical trials of patients (pts) with active PsA.1,2 Recent CorEvitas PsA/SpA Registry analyses…
Abstract Number: 1429 • ACR Convergence 2023
Longitudinal Evaluation of the Novel Psoriatic Arthritis 5-Thermometer Scale (PsA-5Ts) Domains During Treatment with Guselkumab: Pooled Analysis of Three Phase 3, Randomized, Double-blind, Placebo-Controlled Studies
Carlo Selmi¹, Fausto Salaffi², Sibel Aydin³, Enrique Soriano⁴, Emmanouil Rampakakis⁵, Mohamed Sharaf⁶, Miriam Zimmermann⁷, Frederic Lavie⁸, Peter Nash⁹ and Philip J. Mease¹⁰, ¹Rheumatology and Clinical Immunology, Humanitas Research Hospital / Internal Medicine, Humanitas University, Rozzano, Italy, ²Polytechnic University of Marche, Department of Clinical and Molecular Sciences, Carlo Urbani Hospital, Ancona, Italy, ³Department of Medicine, Ottawa Hospital Riverside Campus, Ottawa, ON, Canada, ⁴Rheumatology Section, Internal Medicine Services, Hospital Italiano de Buenos Aires, and University Institute Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁵McGill University, Department of Pediatrics / JSS Medical Research, Scientific Affairs, Montreal, QC, Canada, ⁶Immunology, Janssen MEA, Dubai, United Arab Emirates, ⁷Immunology, Janssen Medical Affairs, LLC, Zug, Switzerland, ⁸The Janssen Pharmaceutical Companies of Johnson & Johnson, Paris, France, ⁹School of Medicine, Griffith University, Brisbane, Australia, ¹⁰Swedish Medical Center/Providence St. Joseph Health and University of Washington School of Medicine, Seattle, WA
Background/Purpose: PsA-5Ts is a simple multidimensional composite measure, assessing pain, fatigue, physical function, skin problems, and depression, recently developed to measure overall health in PsA…
Abstract Number: 1643 • ACR Convergence 2023
Exploring the Serum Metabolome for Potential Diagnostic Markers of Psoriatic Arthritis
Nikita Looby¹, Max Kotlyar², Chiara Pastrello², Darshini Ganatra¹, Vathany Kulasingam³, Igor Jurisica⁴ and Vinod Chandran⁵, ¹Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, ON, Canada, ²Osteoarthritis Research Program, Division of Orthopaedic Surgery, Schroeder Arthritis Institute and Data Science Discovery Centre for Chronic diseases, Krembil Research Institute, Toronto, ON, Canada, ³Department of Laboratory Medicine and Pathobiology, University of Toronto and Division of Clinical Biochemistry, Laboratory Medicine Program, University Health Network, Toronto, ON, Canada, ⁴Schroeder Arthritis Institute, Krembil Research Institute and Departments of Medical Biophysics and Computer Science and Faculty of Dentistry, University of Toronto and Institute of Neuroimmunology, Slovak Academy of Sciences, Bratislava, Slovakia, ⁵Schroeder Arthritis Institute, Krembil Research Institute, University Health Network and Division of Rheumatology, Department of Medicine, University of Toronto, Toronto, ON, Canada
Background/Purpose: Psoriatic arthritis (PsA) is an inflammatory immune-mediated musculoskeletal skin disease that affects approximately 25% of psoriasis patients causing progressive disability. As a heterogeneous disease,…
Abstract Number: 1795 • ACR Convergence 2023
Multi-Omics Analyses Identify Metabolic Pathways That Differentiate Psoriatic Arthritis from Psoriasis
Chiara Pastrello¹, Darshini Ganatra², Max Kotlyar¹, Nikita Looby², Quan Li³, Lihi Eder⁴, Dafna Gladman⁵, Proton Rahman³, Igor Jurisica⁶ and Vinod Chandran⁷, ¹Osteoarthritis Research Program, Division of Orthopaedic Surgery, Schroeder Arthritis Institute and Data Science Discovery Centre for Chronic diseases, Krembil Research Institute, Toronto, ON, Canada, ²Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, ON, Canada, ³Craig Dobbin Research Institute, Memorial University, St. John's, NL, Canada, ⁴Women’s College Research Institute, Division of Rheumatology, University of Toronto, Toronto, ON, Canada, ⁵Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Department of Medicine, University of Toronto, Toronto, ON, Canada, ⁶Schroeder Arthritis Institute, Krembil Research Institute and Departments of Medical Biophysics and Computer Science and Faculty of Dentistry, University of Toronto and Institute of Neuroimmunology, Slovak Academy of Sciences, Bratislava, Slovakia, ⁷Schroeder Arthritis Institute, Krembil Research Institute, University Health Network and Division of Rheumatology, Department of Medicine, University of Toronto, Toronto, ON, Canada
Background/Purpose: Psoriatic arthritis (PsA) is a form of inflammatory arthritis that occurs in patients with cutaneous psoriasis. Due to the lack of clinically useful diagnostic…
Abstract Number: 2235 • ACR Convergence 2023
Identifying Differentially Expressed Genes to Predict TNF-Alpha and IL-17A Inhibitor Response in Psoriatic Arthritis
Quan Li¹, Darren O'Rielly¹, Kari Jenkins¹, Dianne Codner¹, Dafna Gladman², Amanda Dohey¹, Igor Jurisica³, Vinod Chandran⁴ and Proton Rahman⁵, ¹Memorial University, St. John's, NL, Canada, ²Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Department of Medicine, University of Toronto, Toronto, ON, Canada, ³Schroeder Arthritis Institute, Krembil Research Institute and Departments of Medical Biophysics and Computer Science and Faculty of Dentistry, University of Toronto and Institute of Neuroimmunology, Slovak Academy of Sciences, Bratislava, Slovakia, ⁴Schroeder Arthritis Institute, Krembil Research Institute, University Health Network and Division of Rheumatology, Department of Medicine, University of Toronto, Toronto, ON, Canada, ⁵Craig Dobbin Research Institute, Memorial University, St. John's, NL, Canada
Background/Purpose: Approximately 30 to 40% of patients are primary non-responders, and the response rate declines after each successive biological therapy. The primary aim is to…
Abstract Number: 2251 • ACR Convergence 2023
Direct and Indirect Effects of Upadacitinib or Adalimumab on Pain in Psoriatic Arthritis: Results from a Randomized Phase 3 Study
Peter C. Taylor¹, David Walsh², Tsutomu Takeuchi³, Bruno Fautrel⁴, Janet Pope⁵, Koji Kato⁶, Arathi Setty⁶, Tianming Gao⁶, Diane Caballero⁷, Ralph Lippe⁸ and Arthur Kavanaugh⁹, ¹Nuffield Department of Orthopedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ²University of Nottingham, Nottingham, United Kingdom, ³Keio University School of Medicine and Saitama Medical University, Tokyo, Japan, ⁴Sorbonne Université APHP, Paris, France, ⁵University of Western Ontario, London, ON, Canada, ⁶AbbVie, Inc., North Chicago, IL, ⁷AbbVie, Inc., Chicago, IL, ⁸AbbVie Deutschland GmbH & Co. KG, Wiesbaden, Germany, ⁹University of California San Diego, School of Medicine, Riverside, CA
Background/Purpose: Pain, including inflammatory joint pain, may be debilitating in patients with psoriatic arthritis (PsA). Pain in PsA is multidimensional and can be influenced via…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].